Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2020 Oct 26

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Medica 2020 Oct 26

DOI: 10.23736/S0026-4806.20.07082-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Histo-molecular features of high-grade endometrial cancers

Matteo MOROTTI 1 , Hooman SOLEYMANI MAJD 1, Jvan CASARIN 2, Moiad ALAZZAM 1, Stephen DAMATO 3

1 Department of Gynaecology Oncology, Oxford University Hospital NHS Foundation Trust, Oxford, UK; 2 Department of Obstetrics and Gynecology, "Filippo Del Ponte" Hospital, University of Insubria, Varese, Italy; 3 Department of Cellular Pathology, Oxford University Hospitals, Oxford, UK


PDF


High-grade endometrial cancers (ECs) are an aggressive subset of ECs accounting for 70-80% of EC-related deaths. Currently, staging surgery together with chemotherapy or radiotherapy is the main treatment strategy for these cancers. The widespread use of next-generation sequencing has led to a refined understanding of the genomics of EC with important information in term of prognosis as well as the possibility for precision therapies. However, advances in the genomics assessment of high-grade tumours have been slower due to their lower incidence compared to lowgrade EC. In this article, we will briefly the current state of knowledge of the genomics of G3 endometrioid EC, serous uterine cancer, clear cell carcinoma and uterine carcinosarcoma and discussed its implications for diagnosis and targeted therapy.


KEY WORDS: Endometrial Cancer; Genomics; High-grade tumours; Molecular classification; Targeted therapy

top of page